The healthcare sector in India is growing like never before, and regional hospital chains are quietly becoming powerful investment opportunities. One such upcoming issue creating buzz in the primary market is the Gujarat Kidney and Super Speciality IPO.
This IPO gives investors a chance to participate in a fast-expanding regional healthcare provider with a strong presence in Gujarat.
In this detailed article, we will break down everything you need to know—GMP, IPO price, dates, financials, strengths, risks, allotment details, and whether this IPO is worth subscribing to.
About Gujarat Kidney and Super Speciality Limited
Gujarat Kidney and Super Speciality Limited is a regional healthcare provider headquartered in central Gujarat. As of 20 March 2025, the company operates:
-
- 6 multispeciality hospitals
-
- 3 in-house pharmacies
The hospitals are strategically located in Vadodara, Godhra, Bharuch, Borsad, and Anand, catering to both urban and semi-urban populations.
Business Model and Services
The company offers integrated healthcare services, including:
-
- Secondary (surgical) care
-
- Tertiary (super-speciality surgical) care
-
- Diagnostic services
-
- Pharmacy operations
Think of it as a one-stop healthcare ecosystem rather than just a hospital chain.
Hospital Network and Infrastructure
-
- Total beds: 400
-
- Approved beds: 355
-
- Operational beds: 250
This indicates strong scope for scaling operations without heavy incremental capital expenditure in the near term.
Presence Across Gujarat
Instead of chasing metro cities blindly, Gujarat Kidney focuses on underpenetrated healthcare markets—a smart strategy where demand is high and competition is relatively low.
[articlepage]
Strength of Gujarat’s Regional Healthcare Market
Healthcare demand in Gujarat has been rising steadily due to population growth, lifestyle diseases, and better awareness.
Focus on Underpenetrated Markets
Tier-2 and Tier-3 cities often lack quality super-speciality hospitals. Gujarat Kidney effectively fills this gap, creating a strong moat.
Role of Government Healthcare Schemes
The company actively serves patients under Ayushman Bharat – PMJAY, ensuring steady patient inflow and predictable revenue.
You may like to read: Beginners 21 Day Options Trading Rules To Become a Profitable Trader
Gujarat Kidney and Super Speciality IPO Details
IPO Dates and Schedule
-
- IPO Opening Date: 22 December 2025
-
- IPO Closing Date: 24 December 2025
-
- Allotment Finalisation: 26 December 2025
-
- Listing Date: 30 December 2025
IPO Price Band
-
- Price Band: ₹108 – ₹114 per share
-
- Face Value: ₹2 per share
Issue Size and Structure
Fresh Issue Details
-
- Shares Offered: 2,20,00,000
-
- Issue Size: ₹237.6 – ₹250.8 crore
Offer for Sale Status
-
- Offer for Sale: Nil
This means 100% of the proceeds go to the company, which is always a positive sign.
Minimum Investment (Retail Investors)
-
- Lot Size: 128 shares
-
- Minimum Investment: ₹14,592
[articlepage]
Gujarat Kidney IPO GMP (Grey Market Premium)
As of now, the Gujarat Kidney IPO GMP is awaited. GMP usually gives a short-term sentiment check, but remember—fundamentals matter more than grey market noise.
Financial Performance Analysis
Let’s look at how the company has performed financially.
Revenue Growth Trend (₹ in Crores)
-
- FY2023: 85.79
-
- FY2024: 103.44
-
- FY2025: 119.97
Revenue growth shows a consistent upward trajectory, indicating expanding operations and increasing patient footfall.
Profitability and Margin Expansion
-
- Net Profit FY2023: 6.35
-
- Net Profit FY2025: 15.13
-
- Net Margin improved from 7.40% to 12.61%
This is a strong indicator of operational efficiency and cost control.
[articlepage]
Valuation Analysis
EPS and PE Ratio Explained
-
- FY2025 Pre-Issue EPS: 2.89
-
- FY2025 Post-Issue EPS: 1.92
-
- PE Ratio (Post Issue): 56.25 – 59.38
The valuation appears on the higher side, especially when compared with peers.
Comparison with Listed Peers
| Company | PE Ratio | EPS | RONW (%) | Revenue (₹ Cr) |
| Gujarat Kidney | 59.38 | 1.92 | 38.38 | 119.97 |
| Yatharth Hospital | 28.64 | 14.46 | 13.09 | 670.55 |
| GPT Healthcare | 23.66 | 5.96 | 21.86 | 400.19 |
Clearly, Gujarat Kidney is priced at a premium.
Utilization of IPO Proceeds
The company plans to use funds for aggressive expansion.
Major Objectives
-
- Acquisition of Parekhs Hospital, Ahmedabad – ₹77 crore
-
- Payment for Ashwini Medical Centre – ₹12.40 crore
-
- Increasing stake in Harmony Medicare Pvt Ltd – ₹10.78 crore
-
- New hospital in Vadodara – ₹30.10 crore
-
- Robotics equipment – ₹6.83 crore
-
- Debt repayment – ₹1.20 crore
-
- General corporate purposes
This shows a clear growth roadmap.
Strengths of Gujarat Kidney and Super Speciality IPO
-
- Strong regional brand in Gujarat
-
- Presence in underpenetrated healthcare markets
-
- Consistent revenue and profit growth
-
- Improving margins and ROCE
-
- Experienced doctor-led promoter team
-
- No Offer for Sale (company gets full funds)
Risks and Weaknesses
-
- High valuation compared to peers
-
- Dependence on the Gujarat region
-
- The healthcare business is capital-intensive
-
- Regulatory and pricing risks under government schemes
Promoters and Management Profile
Promoters include:
-
- Dr Pragnesh Yashwantsinh Bharpoda
-
- Dr Bhartiben Pragnesh Bharpoda
-
- Dr Yashwantsingh Motisinh Bharpoda
-
- Anitaben Yashwantsinh Bharpoda
A doctor-led management team brings operational expertise and credibility.
[articlepage]
Gujarat Kidney IPO Allotment Status
The allotment status will be available on MUFG Intime India Private Limited’s website after finalisation on 26 December 2025.
IPO Listing Date & Expected Performance
-
- Listing Date: 30 December 2025
-
- Listing on: BSE & NSE
Listing performance will depend on market sentiment and GMP, but long-term performance depends on execution.
Lead Manager and Registrar
-
- Lead Manager: Nirbhay Capital Services Pvt Ltd
-
- Registrar: MUFG Intime India Pvt Ltd
Should You Invest in Gujarat Kidney and Super Speciality IPO?
If you are a long-term investor who believes in India’s regional healthcare growth story, this IPO can be considered.
However, due to high valuation, conservative investors may wait for post-listing opportunities.
Conclusion
The Gujarat Kidney and Super Speciality IPO represents a solid regional healthcare growth story with strong fundamentals, expanding infrastructure, and an experienced promoter team.
While valuations are aggressive, the company’s growth trajectory and expansion plans make it an interesting bet for long-term investors who can tolerate short-term volatility.